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Background: Exome sequencing is a promising method for diagnosing patients with a complex phenotype.
However, variant interpretation relative to patient phenotype can be challenging in some scenarios, particularly
clinical assessment of rare complex phenotypes. Each patient’s sequence reveals many possibly damaging variants
that must be individually assessed to establish clear association with patient phenotype. To assist interpretation, we
implemented an algorithm that ranks a given set of genes relative to patient phenotype. The algorithm orders
genes by the semantic similarity computed between phenotypic descriptors associated with each gene and those
describing the patient. Phenotypic descriptor terms are taken from the Human Phenotype Ontology (HPO) and
semantic similarity is derived from each term’s information content.
Results: Model validation was performed via simulation and with clinical data. We simulated 33 Mendelian diseases
with 100 patients per disease. We modeled clinical conditions by adding noise and imprecision, i.e. phenotypic
terms unrelated to the disease and terms less specific than the actual disease terms. We ranked the causative gene
against all 2488 HPO annotated genes. The median causative gene rank was 1 for the optimal and noise cases, 12
for the imprecision case, and 60 for the imprecision with noise case. Additionally, we examined a clinical cohort of
subjects with hearing impairment. The disease gene median rank was 22. However, when also considering the
patient’s exome data and filtering non-exomic and common variants, the median rank improved to 3.
Conclusions: Semantic similarity can rank a causative gene highly within a gene list relative to patient phenotype
characteristics, provided that imprecision is mitigated. The clinical case results suggest that phenotype rank
combined with variant analysis provides significant improvement over the individual approaches. We expect that
this combined prioritization approach may increase accuracy and decrease effort for clinical genetic diagnosis.
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Thirty-five years since the introduction of contemporary
DNA sequencing techniques, next generation sequencing
(NGS) methods now enable rapid and inexpensive exome
and whole genome sequencing [1-5]. Many genetic dis-
covery applications such as population level mutation
frequency analyses [6,7] and cancer genomics [8,9] have* Correspondence: peter.white@cchmc.org
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unless otherwise stated.benefited from NGS capabilities. More recently, whole
exome sequencing has played a clinical role for pediatric
Mendelian disease and cancer diagnosis. Application to
clinical rare disease diagnosis, however, remains chal-
lenging for many disorders with complex or multimodal
genetic etiologies, primarily due to the difficulty of interpret-
ing genomic sequence variants relevant to patient phenotypic
features [10-13].
In addition to other factors, clinical interpretation of
NGS results is difficult due to the scale and complexity
of the test output data. Unlike typical clinical diagnostic
tests that provide a small number of data points in wellLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Masino et al. BMC Bioinformatics 2014, 15:248 Page 2 of 11
http://www.biomedcentral.com/1471-2105/15/248understood genes, a patient’s exome or genome usually
contains hundreds or thousands of genetic variants, many
of which require expert analysis to determine clinical rele-
vance. Currently, each patient’s sequence reveals a number
of predicted or possibly damaging variants that must be
individually assessed for biological impact to gene func-
tion. However, variant impact to gene function alone is
insufficient to determine clinical relevance. Clear associ-
ation between a gene harboring a damaging variant and
patient phenotype is also required for accurate clinical
diagnosis. This gene-to-patient phenotype analysis is
currently difficult for several reasons. First, there are
tens of thousands of known gene-to-phenotype associa-
tions with various degrees of penetrance, which pre-
cludes individual expert assessment by a review process.
Also, in many cases no single variant explains all pheno-
typic features present in a given patient, while several
variants may explain a subset of the features. These
complications typically require the involvement of a
team of highly trained specialists to identify the variant(s)
causative of patient phenotype, a process that is challen-
ging with respect to expected future demand for clinical
sequencing of cases with a complex genetic etiology
[14,15]. Analogous to the development of tools that aid
variant biological impact assessment; similar methods
for systematic phenotype analysis would likely assist
this process [16,17].
One approach to simplify NGS-aligned phenotype ana-
lysis is the use of gene lists. In this method, a predeter-
mined set of genes with known or suspected pathogenicity
for a diagnostic category (e.g., intellectual disability) is
created, and variant analysis is restricted to this subset of
candidate variants. In effect, the gene list is used as a
phenotype filter applied prior to additional analysis. While
this method provides some systematic phenotypic ana-
lysis, it has important drawbacks. It can be difficult to
reach consensus on the number and breadth of pheno-
typic categories and the genes that should be included
within a given category. Additionally, the lists require con-
tinual curation to remain current with new findings. Most
importantly, the applied list acts as an inflexible filter that
either strictly includes or excludes genes from further
analysis.
A number of approaches have exploited prior gene
knowledge, genomic, functional, and population struc-
ture features for variant prioritization and prediction of
NGS data. Similarly, existing commercial tools, such as
those offered by Cypher Genomics and Ingenuity, utilize
proprietary algorithms to provide phenotype analysis for
variant interpretation. However there is a need for con-
tinued research to develop improved, openly available
methods that incorporate patient clinical phenotype for
automated variant classification. Here, we implement
and validate an algorithm that automatically ranks agene set relative to provided phenotype descriptors. Al-
gorithm performance is analyzed under a variety of sce-
narios intended to mimic clinical diagnostic conditions.
The algorithm utilizes the concept of semantic similarity,
which has been applied in a variety of biological studies
[18-21]. The work presented in [21] used semantic simi-
larity to rank candidate disease diagnoses relative to se-
lected ontology terms describing patient phenotype. Our
approach is similar but ranks candidate genes rather
than diseases. Specifically, our model ranks genes by the
semantic similarity between patient phenotype features
and phenotype features directly associated with each of a
patient’s mutated genes. The model validation results
demonstrate that, in combination with the many diverse
variant features currently considered by diagnostic labora-
tories, phenotypic similarity measures can provide value
for variant prioritization in a clinical setting.Results and discussion
Once a patient’s exome or genome is sequenced, it is ne-
cessary to correlate a mutated gene to the patient’s pheno-
type to reach a clinical diagnosis. Diagnostic complexity
may be reduced if the mutated genes can be automatically
ranked relative to their relation to the patient’s phenotype.
Here, we present simulation and clinical results for a se-
mantic similarity algorithm that provides such a ranked
list. For this exercise, we used the Human Phenotype
Ontology (HPO), a controlled vocabulary organized as a
strict hierarchy that largely represents clinical features and
pathogenic variant data from the Online Mendelian In-
heritance in Man (OMIM) resource and the biomedical
literature.
Our algorithm computes a score for a given gene by
comparing the similarity of HPO terms annotated to the
gene and those used to describe the patient. The similarity
of any two HPO terms is a function of the specificity of
the two terms and their semantic relation. The specificity
of a term is quantified by its information content, IC,
which is a function of the number of genes it annotates
(see Equation 1). There is an inverse relation between IC
and the number of annotated genes, i.e. the more genes a
term annotates, the lower the term’s information content.
In this study, the similarity of two HPO terms is defined
as the IC of the most informative common ancestor of the
two terms (see Equation 2). For example, the similarity of
the terms “Intellectual Disability” and “Specific Learning
Disability” is the IC of the term “Cognitive Impairment” as
illustrated in Figure 1. The maximum similarity between
each patient term and each gene annotation averaged over
the number of patient terms is the similarity score for the
gene (see Equation 3). These scores, with higher scores in-
dicating a stronger predicted relation to the patient pheno-
type, can be used directly to rank genes.
Figure 1 Subsection of human phenotype ontology (HPO).
Terms at left illustrate the ontology’s hierarchical arrangement. The
numbers in parentheses indicate the number of genes that term
directly annotates. A term is considered to annotate a gene if it
directly annotates the gene, as shown in figure, or if it indirectly
annotates the gene through any of its descendants, e.g.
“Abnormality Higher Mental Function” is considered to annotate all
235 genes annotated by “Cognitive Impairment”. The gene list to
the right illustrates how HPO terms are annotated to genes. The
numbers in parentheses indicate the total number of HPO terms
that directly annotate the gene.
Figure 2 Simulated HPO term annotation counts. Distribution of
the number of HPO term annotations per disease for the 33
Mendelian diseases used in the simulation cases (shown in red), and
the number of HPO term annotations per simulated patient (shown
in blue).
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We assessed algorithm performance by the ability to rank
the known causative gene highly within a given gene list.
In each case, we computed the semantic similarity score
between the patient’s phenotype terms and the phenotype
terms associated with the genes in the gene list. We then
sorted the gene list relative to the computed similarity
scores and identified the causative gene’s rank. Addition-
ally, we associated a p-value with each observed score to
account for annotation bias that can occur when objects
are annotated with ontology terms. Bias can result from
differences in curation and because some diseases—and
by extension the related gene—have more phenotypic fea-
tures, e.g. non-syndromic hearing loss vs. neurofibroma-
tosis type 1. Compared to a given query term set, the term
set of a preferentially annotated object is more likely by
random chance to have a higher semantic similarity score
than the term sets of other, less annotated objects. Conse-
quently, the ordering of an object set by comparison of
the semantic similarity score of each object’s annotation
set to the query set can be skewed. To compensate for an-
notation bias, we considered the one-sided p-value associ-
ated with an observed semantic similarity score. As with
the similarity scores, we sorted the gene list relative to the
p-values and identified the causative gene’s rank.Simulation cases
Simulated results were generated for 33 diseases that have
a single known causative gene according to the OMIM
database and for which sufficient phenotype feature pene-
trance data were available to accurately model patient
characteristics [21,22]. For these 33 diseases, the number
of HPO annotations per disease is approximately normally
distributed, with a range from 6 to 50 and a mean of 19.7
(Figure 2). An additional file lists the diseases and their as-
sociated HPO terms and penetrance [see Additional file 1].
For each disease, we first generated 100 simulated patients
by selecting HPO terms for the patient from those terms
directly annotated to the disease gene, with probability de-
termined by the penetrance data (see Methods). This case
is considered optimal and represents a clinical scenario
where the patient phenotype is well recognized and a spe-
cific causative gene is suspected. We then added noise
terms (terms unrelated to the causative gene) to simulate
clinical scenarios where certain patient characteristics are
unrelated to the disease. For each patient, the number of
noise terms was taken to be half the number of optimal
terms, e.g. if a patient had 10 optimal terms, 5 randomly
selected noise terms were added. Finally, we considered
imprecision, which occurs when selected patient terms are
related to the disease but are less specific than the terms
annotated to the causative gene. Imprecision was simu-
lated by randomly replacing each optimal patient term
with one of its ancestor terms. In all, we generated 13,200
simulated patients with a range of HPO annotations be-
tween 1 and 39 and a mean of 9.4 (Figure 2).
For each simulated patient, we ranked the causative gene
against all 2488 genes annotated by at least one HPO term
to evaluate algorithm performance. The causative gene
rank cumulative distribution plots, shown in Figure 3,
summarize the results. The causative gene was ranked first
Figure 3 Causative gene rank cumulative distribution function.
The cumulative distribution function of causative gene rank for the
four simulated scenarios taken across the 33 simulated diseases. The
solid lines are the results obtained when ranked by similarity score.
The dashed lines are the results obtained when ranked by p-value.
The x-axis is the rank, r, and the y-axis is the probability that the
causative gene rank, R, is less than or equal to r. Note that the x-axis
is on a logarithmic scale.
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score and 80% when ranked by p-value. The occurrence of
optimal cases with causative gene ranks other than first is
a result of the patient phenotype annotation process.
Recall that optimal patient terms were selected probabil-
istically based on term penetrance. Thus some optimal pa-
tients had fewer annotations and/or were not annotated
with the important disease terms, specifically those with
higher information content.Figure 4 Noise and imprecision quantification. The color map indicates
equal to r (y-axis) given the similarity value, S (x-axis), between the actual a
with noise and/or imprecision, Pact, and the corresponding optimal patient
between the optimal patient terms so that all values of S are in [0,1].The addition of noise alone did not have substantial
impact on the rankings. When introducing noise, the
causative gene was ranked first for 80.6% of the cases
when ranked by similarity score and 72% when ranked
by p-value. Further, the causative gene was ranked in the
top 10 for greater than 88% of the cases when ranked by
similarity score or p-value.
However, we determined that introducing imprecision
had a large impact. The causative gene was ranked first
for 20% of the cases with added imprecise terms when
ranked by similarity score, and 2% when ranked by p-
value. When we considered introduction of both impreci-
sion and noise, these values fell to 4% and held at 2%
when ranked by similarity score and p-value, respectively.
However, these results are skewed by outliers that occur
for patients with significant amounts of noise and impreci-
sion. This effect is observed in Figure 4, which relates the
quantity of noise and imprecision in the patient terms to
causative gene rank. Specifically, Figure 4 illustrates the
probability that the causative gene is ranked above a cer-
tain value as a function of the similarity between the opti-
mal patient terms and the corresponding patient terms
with noise and/or imprecision when ranked by similarity
score. The figure indicates that when this similarity is
greater than 0.5—when the noise and imprecision terms
are not too severe—the causative gene is ranked in the top
20 genes for at least 80% of cases. Indeed, the median
causative gene ranks were 12 and 60 respectively for cases
with imprecision, and imprecision with noise cases when
ranked by similarity score. Thus, for the majority of cases,
the causative gene was ranked in the top 2.5%. Note thatthe probability that the actual causative gene rank, R, is less than or
nd optimal patient, that is the similarity between the patient terms
terms, Popt. Similarity values are normalized by the self-similarity
Figure 6 Patient HPO annotation count impact. The causative
gene mean rank when ranked by similarity score as a function of
the number of HPO terms used to describe the patient.
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0.8 is likely a result of the specific random patients gener-
ated in this study. Given more samples, we expect that the
maximum would shift toward S = 1.0. However, the gen-
eral trend observed in the plot of decreasing rank (increas-
ing performance) with increasing S would be maintained
with more samples and is indicative of the algorithm’s per-
formance relative to imprecision and noise.
There is some indication that inclusion of patient exome
or whole genome data can further improve results under
these conditions. As described in the clinical results sec-
tion, patient NGS data can be used to filter predicted non-
damaging variants and common variants, which reduces
the gene list length. Additionally, the reduced gene list can
be used to guide patient phenotype feature selection, a
topic we discuss further below.
The noise and imprecision analysis on algorithm per-
formance suggests possible guidelines for selecting pa-
tient terms in clinical practice. In particular, it appears
that the algorithm performs better when provided pa-
tient terms that are very specific, and by having a large
number of relevant terms (Figures 5 and 6). Comparison
of the noise-with-imprecision case to the noise-only and
imprecision-only cases in Figure 5 indicates that select-
ing very specific terms can help counter noise. As with
Figure 4, the minimum rank (best performance) that oc-
curs as the maximum IC reaches 7 in Figure 5 is likely a
result of the specific random sample observed in this
study. Given more samples, we expect that the best per-
formance would shift toward a maximum IC of 8, which
is the maximum possible for the particular annotation
set used. Again, we expect that the general trend observed
in the plot of decreasing rank (increasing performance)
with increasing maximum IC would be maintained with
more samples. Figure 6 indicates that both imprecisionFigure 5 Patient HPO annotation information content impact.
The causative gene mean rank when ranked by similarity score as a
function of the maximum information content, IC, of all HPO terms
used to describe the patient. Higher information content indicates
higher term specificity.and noise effects can be countered by selecting a large set
of patient terms, provided that the terms are relevant to
the disease condition.
Clinical cases
To provisionally evaluate the algorithm in a clinical work-
flow, we measured performance for four actual clinical
cases with hearing impairment. A single genetic counselor
provided clinically relevant patient phenotypes for each of
the four subjects as part of a retrospective exome sequen-
cing validation study. Notably, for more complex pheno-
types it is likely that multiple clinicians may collectively
select patient phenotype terms. In such cases, variability
in term selection between clinicians is possible and may
increase imprecision. The counselor was allowed to select
any HPO phenotype term deemed clinically relevant,
i.e. term-to-gene annotation information was not provided
as might be done to mitigate noise and imprecision. Terms
were selected for a given patient using a custom web appli-
cation that enables HPO term searches by integration with
NCBO web services. The web application associates the
selected terms with a patient ID and stores the terms for
later use. Semantic similarity scores were determined for
each case prior to considering genomic sequence data.
Subsequently, exome sequence data was obtained for each
case. Similarity scores were then recalculated considering
only the subset of genes that contained one or more infre-
quent or rare variants in each individual patient.
Table 1 provides causative gene ranks for the four hear-
ing impaired subjects. The patient annotations ranged
from 2 to 6 HPO terms. When compared to all 2488 HPO
annotated genes, the causative gene exhibited a mean rank
of 22.25 (range: 1–44) when ranked by similarity score and
76.5 (range: 24–218) when ranked by p-value.
After consideration of exome data for each patient and
filtering out non-exomic and common variants, each pa-
tient contained variants in approximately 125 genes (mean:
Table 1 Clinical cases causative gene rank













USH2A 2 12 38 113 2 1
CDH23 6 32 24 125 4 3
SLC26A4 4 1 26 135 1 1
GJB2 3 44 218 129 4 16
Causative gene ranks for patients with hearing impairment. Gene: the
causative gene for each case. Terms: the number of HPO phenotype terms
assigned to the subject by the genetic counselor. HPO Sim Score Rank: the
calculated causative gene rank using the semantic similarity score compared
to all 2,488 HPO annotated genes. HPO p-value Rank: the calculated causative
gene rank using the p-value compared to all 2,488 HPO annotated genes.
Variant Gene Set: the number of genes with variants identified in the patient
of interest. The variant gene set represents genes for which the patient had
exonic or splice site variants that occur with a minor allele frequency: <10% in
CHOP’s internal cohort or <3% in exomes from either the 1000 Genomes
Project [23] or the NHLBI Exome Variant Server [24]. Gene Set Sim Score Rank:
the calculated causative gene rank using the semantic similarity score when
compared to the subset of genes included in that patient’s variant gene set.
Gene Set p-value Rank: the calculated causative gene rank using the p-value
when compared to the subset of genes included in that patient’s variant
gene set.
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of variant-associated genes, the causative gene demon-
strated a mean rank of 2.75 (range: 1–4) when ranked by
similarity score and 5.25 (range: 1–16) when ranked by p-
value. Although preliminary, this result implies that com-
bining phenotypic information via the semantic similarity
score with population and structural information may pro-
vide a significant improvement in the ability to identify pa-
tient causative variants in certain patient populations.
As noted, our method is similar to the tool presented in
[21], Phenomizer, which ranks candidate diseases relative
to patient phenotype. Where possible, the Phenomizer tool
also provides genes known to be associated with each dis-
ease, thereby providing an indirect gene rank mechanism.
However, the resulting Phenomizer gene rank is based on
HPO term-to-disease annotations whereas the method
presented here provides gene ranks based on HPO term-
to-gene annotations. These two annotation sources, term-
to-disease and term-to-gene, have different distributions.
The annotation differences arise because many of the an-
notated diseases lack specific gene associations and many
diseases are associated with multiple genes that individu-
ally are not associated with all of the phenotype character-
istics associated with the disease. Consequently, the two
methods yield different gene rank results. For example, for
the four clinical cases presented here, Phenomizer yields
mean causative gene ranks of 29.25 and 111.75 out of the
2488 annotated genes when ranked by similarity score and
p-value, respectively. Selection of one approach over the
other depends on the clinical scenario. However, in cases
where whole exome or whole genome sequencing is per-
formed and information specific to gene rank is sought,
the presented method is likely advantageous, as it is basedon direct phenotype term-to-gene knowledge and appears
to rank the causative gene more highly.
Conclusion
These results suggest that semantic similarity can rank a
causative gene highly within a gene list relative to patient
phenotype characteristics. The algorithm demonstrates
good performance in the presence of noise, provided that
imprecision is mitigated. Further, the clinical case results
suggest that phenotype rank combined with variant ana-
lysis can substantially improve results over the individual
approaches, at least within the diagnosis of hearing im-
pairment. These conditions approximate a typical rare dis-
ease diagnosis analysis scenario that exists after a patient’s
sequence results are complete and a set of genes with
identified variants is produced. In this case, noise and im-
precision can be mitigated if patient phenotype term se-
lection is restricted to a subset of HPO terms, namely the
terms annotated to the patient’s variant genes.
While the clinical application has been applied here only
to a small number of cases associated with a single diag-
nostic category, these results are encouraging, as they sug-
gest that careful annotation of phenotype by clinical staff
can dramatically improve gene rankings, and thus could
significantly reduce analysis time in certain rare disease
cases, when assessed in context with additional genomic
and clinical data. However, careful annotation of cases in a
busy clinical setting presents workflow and expertise resour-
cing challenges. To mitigate these obstacles, we are currently
developing software that will assist patient phenotype se-
lection through use of the known term information con-
tent and intelligent term suggestion.
As compared to phenotype-based gene lists, the seman-
tic similarity-ranked patient gene list provides at least two
advantages. First, the relative order provides more infor-
mation in the situation where the patient’s mutated gene
set contains multiple genes from the assigned gene list. In
this situation, a gene list does not prioritize amongst mul-
tiple genes, and hence all must be investigated equally.
The rank ordered list, however, assigns a score to each
gene that indicates the strength of association between the
gene and the patient’s clinical presentation. Genes with
very low scores are unlikely to be associated with the pa-
tient’s specific phenotype and should not require detailed
review. If we assume there is a reliable mechanism to de-
termine a similarity score or p-value threshold to delineate
genes unassociated with patient phenotype, we may expect
reduced analysis duration. Secondly, unlike a phenotype-
specific gene list, the rank ordered list is inclusive of all an-
notated genes, not just those on the phenotype specific
gene list, which may not be comprehensive for the pheno-
type. Indeed, this was encountered in a hearing impair-
ment subject whose causative mutation occurred within the
CDH23 gene. A team of physicians and genetic counselors
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pairment gene list for use at The Children’s Hospital of
Philadelphia. The hearing impairment gene list is available
as an additional file [Additional file 2]. The list was created
to support WES clinical analysis conducted for ongoing
research within the National Institutes of Health (NIH)
Clinical Sequencing Exploratory Research (CSER) consor-
tium and was used in the initial analysis for the cited case.
However, the gene list did not include CDH23 and the
diagnosis was missed. In contrast, our semantic similarity
algorithm ranked the CDH23 gene 2nd among the 125
genes with variants of interest. This is an anecdotal case
but it illustrates the challenge with curating phenotype
based gene lists.
An important algorithm limitation is that it is knowledge-
based and is therefore limited by the gene annotation
sources being considered. As such, the system cannot rank
any gene that is not annotated by at least one HPO term
and is dependent upon available gene-to-HPO term map-
pings. In such cases, the unranked genes should be clearly
delineated. Although we focused initially on HPO, we
have designed the algorithm to easily consider additional
disease-based ontologies and expect that more compre-
hensive vocabularies and term-to-gene mappings will
emerge over time. Another limitation is that the algorithm
does not consider pertinent negative annotations, i.e. the
indication that relevant phenotypic terms are not present
in the patient. Inclusion of negation information could be
valuable but may likely require better disease term pene-
trance data to develop adequate scoring models.
Currently, good algorithm performance is constrained
to the clinical diagnostic scenario described above in order
to mitigate imprecision. If imprecision degradation can be
reduced or eliminated (e.g., when applied to disorders
with strong genotype-to-phenotype correlations), algo-
rithm applicability may expand to other scenarios, such as
pre-test decision support for appropriate genetic test se-
lection. A first step in this regard is to develop high-
resolution similarity score distribution models to obtain
accurate p-values that can serve as a test validation
measure. For example, assume the top ranked gene has
a similarity score, s, with an associated p-value, α. The
absolute similarity score, s, only provides an inter-gene
comparison mechanism but does not indicate the statis-
tical significance of the relation between the top ranked
gene and the patient phenotype. A p-value would pro-
vide such a statistical significance measure. Note, in this
context it is necessary to correct for multiple testing
[25]. We are currently developing similarity score distri-
bution models with higher resolution than our initial
versions that will enable reliable p-value calculations to
indicate test validity.
Exome sequencing capabilities have enabled advance-
ments in a number of genetic research domains, clinicaldiagnosis of Mendelian disease, and clinical oncology.
However, application of genomic sequencing as a clinical
diagnostic test has been more difficult to achieve for
many rare diseases. In part, this difficulty results from
the complicated process of associating predicted deleteri-
ous variants to observed patient phenotype. Moreover,
clinical application of NGS technologies to rare disease
must often address a wide phenotype spectrum. Specific
phenotype combinations will vary widely in their ability
to precisely define genes. For example, the search query
“microcephaly, oligodactyly, diaphragmatic hernia, hyper-
trichosis” produces exactly one OMIM result, Cornelia
De Lange Syndrome. Other phenotypes are more diffi-
cult to diagnose because they are common and exhibit
genetic heterogeneity. Our clinical results are encouraging
because the hearing disorder phenotype is especially diffi-
cult to diagnose; indeed, the search query “hearing loss”
yields greater than 1000 OMIM results. With continued
research, we expect the algorithm presented here may play
an integral role for NGS-based clinical diagnosis, espe-
cially when used in combination with other genomic,
population, and predictive variant annotations.
Methods
Development of our prioritization model required a con-
trolled vocabulary to describe phenotypes and knowledge
of the semantic relationships between the vocabulary terms.
Additionally, the genes that are to be ranked must be anno-
tated with the appropriate vocabulary terms. The first two
requirements are satisfied using an ontology that includes
a shared vocabulary and defined relationships between vo-
cabulary terms. Appropriate annotation of ontology terms
to genes satisfies the last requirement. For the work pre-
sented here, we used the Human Phenotype Ontology
(HPO) [26-28], which was specifically developed to repre-
sent human disease phenotypic abnormality knowledge.
HPO concepts are organized in a strict hierarchy, where
child terms assume “is-a” relationships with their ancestor
terms. In addition to the ontology, the HPO resources in-
clude a gene-to-phenotype mapping that provides known
associations between Entrez gene IDs [29,30] and HPO
terms. The true-path rule applies to all annotations, such
that if a gene is annotated with a specific HPO term, it in-
herits all ancestors of that term. The specific files used for
this work were hp.obo build 687, and genes-to-phenotype
build 26. This HPO version contains 9,965 phenotype
terms, of which 6,346 either directly or indirectly annotate
at least one gene. The genes-to-phenotype file provides
61,784 direct annotations for 2,488 genes.
Semantic similarity
Our model is based on a concept known as semantic simi-
larity. We assume that ontology terms are used to anno-
tate a set of objects, and that the true-path rule applies for
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more or less specific than others with respect to the
number of objects it annotates. Consider two terms sets,
P1 = {p1,p2,…,pK} and P2 = {p1,p2,…,pJ}, selected from the
ontology. Given the semantic structure of the ontology
and the specificity of the terms, we can compare the
similarity, or likeness, of these sets with an appropriate
semantic similarity model.
Our semantic similarity model requires a mathematical
description of each ontology term’s specificity. Given an
ontology term, p, we quantify the term’s specificity using
its information content, IC, as defined by Resnik [31]:




where N is the total number of objects annotated by
all terms and np is the number of objects annotated either
directly or indirectly, via the true-path rule, by the term p.
Given two terms p1 and p2, let A(p1,p2) be the set of all
common ontological ancestors of p1 and p2, noting that p1
and p2 are not included in A unless p1 = p2. We define the
most informative common ancestor of p1 and p2, pMICA,
to be the term in A with the maximum information con-
tent. We define the termwise semantic similarity as [21]:





where npMICA is the number of objects annotated directly
or indirectly by the term pMICA.
In order to compare two term sets, we require a term-set
semantic similarity model. Given two arbitrary term sets,
P1 = {p1,p2,…,pK} and P2 = {p1,p2,…,pJ}, we define the asym-
metric term-set semantic similarity as:





simX pk ; pj
 
ð3Þ
where simX is a termwise similarity function such as
Equation 2. Note, Equation 3 is asymmetric, i.e., its out-
put is dependent on the order of the arguments P1 and
P2. A symmetric term-set semantic similarity model can
then be constructed as follows:
simsym P1;P2; simXð Þ ¼ simasym P1→P2; simXð Þ þ simasym P2→P1; simXð Þ2
ð4Þ
Note that Equations 3 and 4 describe a family of se-
mantic similarity models that depend on the termwise
comparison function simX, a number of which are de-
scribed in the literature [21,31,32].
Given a term-set semantic similarity model, we can
rank an annotated object set relative to some query set.Here, we wish to rank a list of genes relative to a query
set that represents the patient’s phenotype. We first assume
that a set of HPO phenotype terms, Pp = {p1,p2,…,pK}, is
used to characterize patient abnormalities, and that any
given gene, g, is annotated with a set of phenotype terms,
Pg = {p1, p2, . . . , pJ}, that indicate a known link between
mutations in the gene and the associated phenotype ab-
normalities. For each gene, we assign a score computed as
the semantic similarity between Pp and Pg and then sort
the genes in descending order based on the assigned
score. In the event of identical values across multiple
genes, all equivalent genes are assigned a rank equal to
the mean of the sequential positions. For example, if four
genes all have the same similarity score and the four genes
occupy positions {i, i + 1, i + 2, i + 3} in the sorted list, then
each gene is assigned the rank (4i + 6)/4, rounded down to
the nearest integer.
Statistical significance
To compensate for annotation bias, objects can be or-
dered by some statistical significance measure of the se-
mantic similarity observed between the query term set
and the terms annotated to each object. Specifically, we
computed the one-sided p-value associated with an ob-
served semantic similarity score. A similarity score distri-
bution model is required for each annotated object and
for each fixed query term set length to determine the p-
value of an observed similarity score. We consider two ob-
jects, g1 and g2, each annotated with different ontology
terms, assuming K1 ontology terms are randomly selected
to represent the query set and that the semantic similarity
between the query set and the terms annotated to g1 and
g2 are recorded. The score distribution observed for g1 will
differ from that observed for g2. Similarly, the distribution
obtained for g1 with randomly selected query sets with K2
terms will differ from the distribution for g1 with query
sets with K1 terms provided K2 ≠K1.
Assuming we have similarity score distribution models
for each gene annotated by HPO terms for each pheno-
type query set length, K, and given an HPO phenotype
query set representing a patient’s phenotypes, we can
compute a semantic similarity score for each gene in some
gene set as described in the previous section. If we now
assign to each gene the p-value associated with the seman-
tic similarity score observed for that gene, we rank the
genes in ascending order by p-value. If two or more genes
have the same p-value, their relative rank is determined
using the similarity scores. For example, if four genes have
the same p-value and occupy positions {i, i + 1, i + 2, i + 3}
in the sorted list, each gene is assigned the rank i − 1 + sr
where sr is the gene’s position amongst the four genes
when sorted by similarity score.
It is not computationally feasible to sample the entire
similarity score space for all genes annotated by HPO
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sets grows exponentially with query set length, K. Con-
sequently, we estimated the similarity distribution
models using Monte Carlo sampling. For each combin-
ation of gene and query set length in the range [2,10],
we randomly selected 100,000 query phenotype sets and
computed the corresponding semantic similarity to the
terms annotated to the gene. Note that for k = 1, we
sampled the entire space of 6,346 query terms. The
Monte Carlo sampling was conducted using a custom
Scala Akka application deployed on Amazon’s Elastic
Compute Cloud [33-35].
From the Monte Carlo samples, we created tables
representing the similarity score cumulative distribution
function (CDF) for each gene and patient phenotype set
length combination. Given a similarity score, s, for gene,
g, and patient phenotype set length, K, we estimate the
one-sided p-value for the probability of randomly
obtaining a similarity score greater than or equal to the
observed score from the CDF as:
1−CDF s; g; kð Þ; ð5Þ
For query phenotype sets of length greater than 10, we
used the tables derived for K = 10.
Data generation
For a given disease, we formed a baseline disease pheno-
type feature set as the intersection of the disease terms
supplied in the online version of [21] and those annotated
to the Online Mendelian Inheritance in Man (OMIM)-in-
dicated causative gene, per the HPO resource file gene-to-
phenotypes. The penetrance of each disease phenotype
was also taken from the online version of [21]. A complete
list of the disease causative genes and their associated pheno-
types is available as an additional file [see Additional file 1].
We simulated 100 baseline patients per disease. To ac-
count for gender-specific phenotypes, we first generated
a standard uniform random number and designated the
patient as male if the number was greater than 0.5, and
female if ≤0.5. Then, for each baseline phenotype fea-
ture, p, associated with the patient’s disease, we gener-
ated a new standard uniform pseudo-random number,
αp, and added p to the patient’s phenotype set if αp ≤ fp,
where fp is the phenotype penetrance. For example, as-
sume a given disease has two phenotypes, p1 and p2,
with penetrance 0.25 and 0.5, respectively, then for each
simulated patient we generated two random numbers,
αp1 and αp2 . We assigned p1 to the patient if αp1 ≤ 0.25
and likewise assigned p2 if αp2 ≤ 0.5. We tacitly assumed
that disease phenotypes occur independently of each
other because joint distribution data is not currently
available. We ensured that every simulated patient had
at least one phenotype term. We denote this patient cohortas “optimal” to indicate that the patient phenotype charac-
teristics were selected from those directly annotated to the
causative gene.
In actual clinical practice, patient phenotype sets will
often include noise and imprecision. Imprecision occurs
when a less specific phenotype term is used to annotate
the patient in place of the phenotype term annotated to
the causative gene. For example, assume the phenotype,
p1, is directly annotated to the causative gene, g. Let p2
be any ontological ancestor of p1 other than the ontology
root term, and assume that p2 is not annotated to g. We
defined imprecision as present if p2 is used to annotate
the patient instead of p1. We defined noise as occurring
when a phenotype that does not directly or indirectly
annotate a gene is nevertheless assigned to the patient
phenotype set.
To examine the impact of noise, randomly selected
noise terms were added to each patient’s baseline opti-
mal phenotype set. Noise terms were generated separ-
ately for each patient. Each disease was associated with
an allowable set of HPO noise terms, namely all terms
that do not directly or indirectly annotate the disease
causative gene. For each patient, noise terms were se-
lected randomly from the disease specific list so that dif-
ferent patients had different noise terms. The number of
noise terms per patient was set to half the number of
optimal terms, i.e. those derived from terms annotating
the causative gene. For example, if a given patient had 4
optimal terms that patient was assigned 2 additional ran-
domly selected noise terms. If a given patient had 10 opti-
mal terms that patient was assigned 5 additional randomly
selected noise terms. To examine the impact of impreci-
sion, the patient’s optimal phenotypes were each replaced
with a randomly selected ancestor term, other than the
ontology root. For each simulated disease, the terms
directly annotated to the causative gene, i.e. the opti-
mal terms, were assigned an allowed imprecision term
set composed of all ancestor terms of the optimal term.
For each patient, imprecision was added by replacing
every optimal term by a randomly selected term from
the imprecision set for that optimal term so that differ-
ent patients had different imprecision terms. Finally, to
add both noise and imprecision, the noise terms gener-
ated for a given patient in the “noise only” case were
added to the patient terms generated in the “impreci-
sion only” case.
In addition to the simulated data, we also obtained
data for actual clinical patients taken from a research
cohort currently used as part of a clinical genomics
workflow validation project at The Children’s Hospital
of Philadelphia and the Perelman School of Medicine
at the University of Pennsylvania. The purpose of this
project is to validate the ability of the exome sequen-
cing workflow to enable the identification of causative
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eases with a previously identified causative variant con-
firmed by Sanger sequencing. In the validation study,
retrospective exome sequencing was performed for each
subject. Genetic counselors, who were not provided the
known causative variant, then examined the exome se-
quence results to identify the causative variant. For a
number of these retrospective cases, a genetic counselor
provided a list of patient HPO phenotype characteristics
deemed relevant to the patient’s condition, which were
used to evaluate the semantic similarity algorithm. This
research was approved by the Institutional Research
Board of The Children's Hospital of Philadelphia. Writ-
ten informed consent was obtained from the patient for
the publication of this report and any accompanying
images.
Data access
Two additional files accompany this article. “Additional file 1”
is a .pdf file that contains the OMIM disease ID, name,
causative gene, associated HPO terms and penetrance
values used for the 33 simulated Mendelian diseases used
in this study. “Additional file 2” is a .txt file containing the
hearing loss phenotype gene list developed at The Chil-
dren’s Hospital of Philadelphia and used for evaluation of
the clinical cases in this study. The custom source code
used to implement the algorithm and generate the simu-
lated data in this work is publically available at: https://
github.com/cbmi/phenomantics.
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